Atomoxetine is a non‐stimulant drug licensed for use in the treatment of attention deficit‐hyperactivity disorder (ADHD).Dr Banerjee describes a study that was carried out over a two‐year period in the three ADHD clinics in East Kent Hospitals NHS Trust to evaluate the current practice on the use of atomoxetine in ADHD in children and adolescents. Copyright © 2009 Wiley Interface Ltd